{
  "paper_metadata": {
    "pmid": "35534218",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for BRCA2, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.1310_1313del",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 2,
        "demographics": "Korean men with prostate cancer",
        "phenotype": "male breast cancer and prostate cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 2,
        "affected_count": 1,
        "unaffected_count": 1,
        "uncertain_count": null,
        "penetrance_percentage": 50.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "diagnosed with male breast cancer during hormonal treatment of prostate cancer",
          "evidence_sentence": "One patient with regional prostate cancer who had the BRCA2 variant (c.1310_1313del) was diagnosed with male breast cancer during hormonal treatment of prostate cancer."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "localized prostate cancer with intermediate-risk",
          "evidence_sentence": "Although genetic testing is not recommended for patients with intermediate-risk prostate cancer, the percentage of positive variants in patients with the intermediate-risk disease (5.9%, 2/34) was comparable to that in patients with high, very high, regional, or metastatic disease (6.6%, 5/76)."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 variant is associated with an increased risk of prostate cancer and male breast cancer.",
        "assays": []
      },
      "segregation_data": "Not explicitly mentioned.",
      "population_frequency": null,
      "evidence_level": "Moderate evidence based on ACMG/AMP guidelines.",
      "source_location": "Results, paragraph 4",
      "additional_notes": "This is the only BRCA2 variant reported in the study.",
      "key_quotes": [
        "One patient with regional prostate cancer who had the BRCA2 variant (c.1310_1313del) was diagnosed with male breast cancer during hormonal treatment of prostate cancer."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data for BRCA2 was extracted successfully."
  }
}